Short description
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of innovative medicines.
Description
Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders.
The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%.
Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.
Last funding
Noaccess
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Tarrytown, New York, United States, North America
Founded on
January 1, 1988
Exited on
April 12, 1991
Went public on
April 12, 1991
Stock symbol
REGN
Non-profit?
No
Acquired?
No
Employees count
5001+
Revenue range
$34056 - 789030
Sign in for full access
Investors
Uh Ohhhh
Sign in for full access
Founders
Eric Shooter, George D. Yancopoulos, Leonard S. Schleifer
Funding rounds count
8
Portfolio organisations count
Noaccess, Noaccess
Sign in for full access
Lead investments count
3
Exits count
Cannot Access, Uh Ohhhh
Sign in for full access
IPO exits count
3